CPRX
Another beat, another “meh?”
Catalyst Pharmaceuticals came out swinging in Q4 2025, reporting adjusted earnings of 68 cents per share. That topped the 42-cent consensus, which is the kind of gap that usually gets investors leaning forward in their chairs.
Revenue did the heavy lifting
Sales came in at $152.6 million, up 8% from a year ago and also above the $140 million estimate. Most of that was product revenue, which tells you the commercial engine is still humming instead of coughing and wheezing.
So why is the stock still acting grumpy?
Because markets are picky little gremlins. The stock is down 2.5% since the last earnings report, so even a clean beat may not be enough if investors were already expecting good news, wanted stronger guidance, or are just looking for the next catalyst. Yes, that word is doing a lot of work here.
Big picture: Catalyst is still doing the basic job well — beat the numbers, grow revenue, keep Firdapse doing its thing — but the market clearly wants a little more sparkle before it rewrites the script.